Synthesis and Evaluation of Anibamine and Its Analogs as Novel Anti-Prostate Cancer Agents
The chemokine receptor CCR5 has been implicated in the pathogenesis of prostate cancer. A novel natural product, anibamine, was isolated and found to be a micromolar inhibitor of the receptor. Anibamine was used as a new anti-prostate cancer lead compound. To discover the pharmacophore, analogs of...
| Main Author: | |
|---|---|
| Format: | Others |
| Published: |
VCU Scholars Compass
2009
|
| Subjects: | |
| Online Access: | http://scholarscompass.vcu.edu/etd/1974 http://scholarscompass.vcu.edu/cgi/viewcontent.cgi?article=2973&context=etd |
| Summary: | The chemokine receptor CCR5 has been implicated in the pathogenesis of prostate cancer. A novel natural product, anibamine, was isolated and found to be a micromolar inhibitor of the receptor. Anibamine was used as a new anti-prostate cancer lead compound. To discover the pharmacophore, analogs of anibamine were designed using the “deconstruction-reconstruction-elaboration” approach and synthesized. The establishment of a stereoselective route to only one isomer was explored, to increase yield and eliminate elaborate purification procedures. Analogs were found to have anti-prostate cancer activity at levels higher than the parent compound. The molecular modeling studies of the deconstructed analogs indicate that due to the psuedo-symmetry of the parent compound, the binding conformation of the deconstructed analogs may not be very different from each other. All this information together may help identify a next generation lead compound for anti-prostate cancer treatment. |
|---|